The use of dopamine replacement therapies (DRT) in the treatment of Parkinson's disease (PD) can lead to the development of dopamine dysregulation syndrome (DDS) and impulse control disorders (ICD), behavioral disturbances characterized by compulsive DRT self-medication and development of impulsive behaviors. However, the mechanisms behind these disturbances are poorly understood. In animal models of PD, the assessment of the rewarding properties of levodopa (LD), one of the most common drugs used in PD, has produced conflicting results, and its ability to promote increased impulsivity is still understudied. Moreover, it is unclear whether acute and chronic LD therapy differently affects reward and impulsivity. In this study we aimed at ass...
Introduction: Chronic dopamine replacement therapies in Parkinson's disease can induce side effects,...
Impulse control disorders (ICD) in Parkinson’s disease (PD) are a disabling non-motor symptom with f...
Rationale: Treatment of Parkinson's disease has been by now symptomatic. The literature on the effic...
The use of dopamine replacement therapies (DRT) in the treatment of Parkinson's disease (PD) can lea...
Dopaminergic medications used in the treatment of patients with Parkinson's disease are associated w...
Impulse control disorders (ICDs) are frequent behavioral complications of dopaminergic (DA) replacem...
Impulse control disorders (ICDs) are frequent behavioral complications of dopaminergic (DA) replacem...
Impulse control disorders (ICDs) are frequent behavioral complications of dopaminergic (DA) replacem...
Dopamine agonist therapy and deep brain stimulation (DBS) are both linked to increased impulsivity i...
Dopamine agonists (DA) that are widely used to treat motor deficits in patients with Parkinson’s d...
Impulse control disorders (ICD) is a common side effect of the dopaminergic treatment in patients wi...
Impulse control disorders (ICDs) are frequent behavioral complications of dopaminergic (DA) replacem...
International audienceDopamine dysregulation syndrome shares some core behavioral features with psyc...
Objective: We here investigated the effect of bilateral 6-hydroxydopamine (6-OHDA) lesions, a rat mo...
A range of pathological behaviours associated with treatment with dopamine receptor agonists (DA) ha...
Introduction: Chronic dopamine replacement therapies in Parkinson's disease can induce side effects,...
Impulse control disorders (ICD) in Parkinson’s disease (PD) are a disabling non-motor symptom with f...
Rationale: Treatment of Parkinson's disease has been by now symptomatic. The literature on the effic...
The use of dopamine replacement therapies (DRT) in the treatment of Parkinson's disease (PD) can lea...
Dopaminergic medications used in the treatment of patients with Parkinson's disease are associated w...
Impulse control disorders (ICDs) are frequent behavioral complications of dopaminergic (DA) replacem...
Impulse control disorders (ICDs) are frequent behavioral complications of dopaminergic (DA) replacem...
Impulse control disorders (ICDs) are frequent behavioral complications of dopaminergic (DA) replacem...
Dopamine agonist therapy and deep brain stimulation (DBS) are both linked to increased impulsivity i...
Dopamine agonists (DA) that are widely used to treat motor deficits in patients with Parkinson’s d...
Impulse control disorders (ICD) is a common side effect of the dopaminergic treatment in patients wi...
Impulse control disorders (ICDs) are frequent behavioral complications of dopaminergic (DA) replacem...
International audienceDopamine dysregulation syndrome shares some core behavioral features with psyc...
Objective: We here investigated the effect of bilateral 6-hydroxydopamine (6-OHDA) lesions, a rat mo...
A range of pathological behaviours associated with treatment with dopamine receptor agonists (DA) ha...
Introduction: Chronic dopamine replacement therapies in Parkinson's disease can induce side effects,...
Impulse control disorders (ICD) in Parkinson’s disease (PD) are a disabling non-motor symptom with f...
Rationale: Treatment of Parkinson's disease has been by now symptomatic. The literature on the effic...